Compare Stocks: HELP, MLYS, HRMY, and HCM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HCM HUTCHMED	$11.66 +0.9%	$10.99	$9.77 ▼ $18.30	$2.03B	0.23	42,174 shs	7,271 shs
HELP Cybin	$10.98 +4.3%	$6.09	$3.76 ▼ $11.48	$765.68M	0.55	1.11 million shs	1.55 million shs
HRMY Harmony Biosciences	$38.49 +0.7%	$34.91	$25.52 ▼ $40.87	$2.23B	0.96	860,863 shs	308,940 shs
MLYS Mineralys Therapeutics	$27.05 +0.7%	$26.66	$12.59 ▼ $47.65	$2.23B	0.68	1.30 million shs	165,464 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HCM HUTCHMED	-0.35%	+1.40%	-0.86%	-13.22%	-35.83%
HELP Cybin	+13.47%	+33.12%	+78.78%	+97.19%	+1,052,999,900.00%
HRMY Harmony Biosciences	-1.39%	+6.76%	+3.32%	+21.71%	+9.44%
MLYS Mineralys Therapeutics	+1.32%	+1.90%	-7.80%	-8.52%	+100.22%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HCM HUTCHMED	$11.66 +0.9%	$10.99	$9.77 ▼ $18.30	$2.03B	0.23	42,174 shs	7,271 shs
HELP Cybin	$10.98 +4.3%	$6.09	$3.76 ▼ $11.48	$765.68M	0.55	1.11 million shs	1.55 million shs
HRMY Harmony Biosciences	$38.49 +0.7%	$34.91	$25.52 ▼ $40.87	$2.23B	0.96	860,863 shs	308,940 shs
MLYS Mineralys Therapeutics	$27.05 +0.7%	$26.66	$12.59 ▼ $47.65	$2.23B	0.68	1.30 million shs	165,464 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HCM HUTCHMED	-0.35%	+1.40%	-0.86%	-13.22%	-35.83%
HELP Cybin	+13.47%	+33.12%	+78.78%	+97.19%	+1,052,999,900.00%
HRMY Harmony Biosciences	-1.39%	+6.76%	+3.32%	+21.71%	+9.44%
MLYS Mineralys Therapeutics	+1.32%	+1.90%	-7.80%	-8.52%	+100.22%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HCM HUTCHMED	2.17	Hold	$14.87	27.56% Upside
HELP Cybin	3.00	Buy	$45.25	312.11% Upside
HRMY Harmony Biosciences	2.50	Moderate Buy	$45.50	18.21% Upside
MLYS Mineralys Therapeutics	2.63	Moderate Buy	$49.33	82.41% Upside

Current Analyst Ratings Breakdown

Latest HELP, MLYS, HRMY, and HCM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/5/2026	HRMY Harmony Biosciences	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold	$39.00
8/5/2026	HRMY Harmony Biosciences	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Hold	$29.00 ➝ $34.00
8/5/2026	HRMY Harmony Biosciences	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$37.00
8/4/2026	HRMY Harmony Biosciences	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$70.00
8/4/2026	HRMY Harmony Biosciences	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$45.00 ➝ $50.00
7/31/2026	HCM HUTCHMED	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C-) ➝ Sell (D)
7/31/2026	HRMY Harmony Biosciences	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$50.00 ➝ $51.00
7/27/2026	HELP Cybin	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$16.00
7/23/2026	HCM HUTCHMED	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$16.00 ➝ $14.00
7/17/2026	HCM HUTCHMED	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C-)
7/17/2026	MLYS Mineralys Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 8/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HCM HUTCHMED	$548.51M	3.71	$2.72 per share	4.29	$7.31 per share	1.59
HELP Cybin	N/A	N/A	N/A	N/A	$4.49 per share	N/A
HRMY Harmony Biosciences	$959.90M	2.32	$3.15 per share	12.20	$17.26 per share	2.23
MLYS Mineralys Therapeutics	N/A	N/A	N/A	N/A	$8.17 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HCM HUTCHMED	$456.91M	N/A	N/A	52.98	N/A	N/A	N/A	N/A	N/A
HELP Cybin	-$148M	-$4.23	N/A	N/A	N/A	N/A	-68.27%	-58.26%	N/A
HRMY Harmony Biosciences	$158.69M	$3.08	12.50	9.95	0.36	18.88%	20.06%	14.15%	N/A
MLYS Mineralys Therapeutics	-$154.65M	-$2.05	N/A	N/A	N/A	N/A	-27.92%	-26.98%	8/11/2026 (Estimated)

Latest HELP, MLYS, HRMY, and HCM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	MLYS Mineralys Therapeutics	-$0.5486	N/A	N/A	N/A	N/A	N/A
8/4/2026	Q2 2026	HRMY Harmony Biosciences	$0.9560	$1.28	+$0.3240	$1.28	$250.77 million	$261.28 million
7/30/2026	H1 2026	HCM HUTCHMED	$0.1450	$0.05	-$0.0950	$0.05	$304.16 million	$139.14 million
5/7/2026	Q1 2026	HRMY Harmony Biosciences	$0.76	$0.55	-$0.21	$0.55	$220.84 million	$215.39 million
5/6/2026	Q1 2026	MLYS Mineralys Therapeutics	-$0.51	-$0.47	+$0.04	-$0.47	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
HCM HUTCHMED	N/A	N/A	N/A	N/A	N/A
HELP Cybin	N/A	N/A	N/A	N/A	N/A
HRMY Harmony Biosciences	N/A	N/A	N/A	N/A	N/A
MLYS Mineralys Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HCM HUTCHMED	0.06	5.64	5.50
HELP Cybin	N/A	9.52	9.52
HRMY Harmony Biosciences	0.13	3.48	3.56
MLYS Mineralys Therapeutics	N/A	44.33	44.33

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HCM HUTCHMED	8.82%
HELP Cybin	17.94%
HRMY Harmony Biosciences	86.23%
MLYS Mineralys Therapeutics	84.46%

Insider Ownership

Company	Insider Ownership
HCM HUTCHMED	3.60%
HELP Cybin	15.00%
HRMY Harmony Biosciences	11.00%
MLYS Mineralys Therapeutics	18.94%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HCM HUTCHMED	1,796	174.47 million	168.19 million	Not Optionable
HELP Cybin	50	69.87 million	59.39 million	N/A
HRMY Harmony Biosciences	200	57.89 million	51.53 million	Optionable
MLYS Mineralys Therapeutics	28	82.50 million	66.87 million	Optionable

HELP, MLYS, HRMY, and HCM Headlines

Recent News About These Companies

Mineralys Therapeutics (MLYS) to Release Quarterly Earnings on Tuesday

August 4 at 12:10 PM | marketbeat.com

Mineralys Therapeutics to Announce Second Quarter 2026 Financial Results and Host Conference Call on Tuesday, August 11, 2026

August 4 at 8:53 AM | markets.businessinsider.com

Mineralys Therapeutics to Report Second Quarter 2026 Financial Results on August 11

August 4 at 8:31 AM | quiverquant.comQ

Renaissance Technologies LLC Purchases 60,700 Shares of Mineralys Therapeutics, Inc. $MLYS

August 3 at 4:55 AM | marketbeat.com

Mineralys Therapeutics, Inc. $MLYS Shares Bought by Stempoint Capital LP

July 30, 2026 | marketbeat.com

Mineralys Therapeutics (NASDAQ:MLYS) Insider Sells $199,859.06 in Stock

July 29, 2026 | insidertrades.com

Mineralys Therapeutics (NASDAQ:MLYS) Insider Eric Warren Sells 7,438 Shares

July 28, 2026 | marketbeat.com

Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

July 27, 2026 | globenewswire.com

Mineralys Therapeutics, Inc. $MLYS Shares Purchased by Orbimed Advisors LLC

July 27, 2026 | marketbeat.com

Troluce Capital Advisors LLC Takes Position in Mineralys Therapeutics, Inc. $MLYS

July 27, 2026 | marketbeat.com

Pale Fire Capital SE Purchases 355,272 Shares of Mineralys Therapeutics, Inc. $MLYS

July 25, 2026 | marketbeat.com

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Receives Consensus Recommendation of "Moderate Buy" from Analysts

July 19, 2026 | marketbeat.com

A Mineralys Insider Banked a $557,000 Options Gain Before a December FDA Date

July 16, 2026 | finance.yahoo.com

Swedbank AB Sells 99,300 Shares of Mineralys Therapeutics, Inc. $MLYS

July 12, 2026 | marketbeat.com

Mineralys Therapeutics, Inc. $MLYS Holdings Raised by Candriam S.C.A.

July 12, 2026 | marketbeat.com

Insider Selling: Mineralys Therapeutics (NASDAQ:MLYS) Insider Sells $65,781.30 in Stock

July 11, 2026 | insidertrades.com

Mineralys Therapeutics (NASDAQ:MLYS) Insider David Malcom Rodman Sells 2,171 Shares of Stock

July 10, 2026 | marketbeat.com

Mineralys Therapeutics (NASDAQ:MLYS) Trading Down 5.5% - What's Next?

July 9, 2026 | marketbeat.com

Y Intercept Hong Kong Ltd Acquires 100,740 Shares of Mineralys Therapeutics, Inc. $MLYS

July 7, 2026 | marketbeat.com

Is Mineralys Therapeutics, Inc. (MLYS) Stock a Biotech Opportunity With Lorundrostat’s Expanding Cardiovascular Potential?

July 2, 2026 | insidermonkey.com

5 Hidden Multibagger Stocks to Buy Right Now

July 2, 2026 | insidermonkey.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

HELP, MLYS, HRMY, and HCM Company Descriptions

HUTCHMED NASDAQ:HCM

$11.66 +0.11 (+0.91%)

As of 01:08 PM Eastern

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

Cybin NASDAQ:HELP

$10.98 +0.45 (+4.27%)

As of 01:09 PM Eastern

Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a discovery-phase phenethylamine derivative to treat neuroinflammation and psychiatric conditions. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.

Harmony Biosciences NASDAQ:HRMY

$38.49 +0.25 (+0.65%)

As of 01:10 PM Eastern

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Mineralys Therapeutics NASDAQ:MLYS

$27.04 +0.20 (+0.73%)

As of 01:09 PM Eastern

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HELP, MLYS, HRMY, and HCM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HELP, MLYS, HRMY, and HCM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HELP, MLYS, HRMY, and HCM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

HELP, MLYS, HRMY, and HCM Company Descriptions

HUTCHMED NASDAQ:HCM

Cybin NASDAQ:HELP

Harmony Biosciences NASDAQ:HRMY

Mineralys Therapeutics NASDAQ:MLYS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HELP, MLYS, HRMY, and HCM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HELP, MLYS, HRMY, and HCM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HELP, MLYS, HRMY, and HCM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

HELP, MLYS, HRMY, and HCM Company Descriptions

HUTCHMED NASDAQ:HCM

Cybin NASDAQ:HELP

Harmony Biosciences NASDAQ:HRMY

Mineralys Therapeutics NASDAQ:MLYS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools